Technical Director, Molecular and Genomics Studies Tennessee Oncology
Liquid biopsy is emerging as a revolutionary technology, promising swift and precise diagnostics. Despite its potential to significantly impact precision oncology, liquid biopsy faces challenges.
Join us for this talk to hear about the collaborative efforts of SOPHiA GENETICS and AstraZeneca in expanding global access to and adoption of MSK-ACCESS® powered with SOPHiA DDM™.
Learn about the decentralized approach, technology, and analytical performance of this liquid biopsy application.
Explore the journey of creating a global network for liquid biopsy testing.
Gain insights from the first hands-on experience with MSK-ACCESS® powered with SOPHiA DDM™ from one of the early-access healthcare institutions.
